CLRB News and Press, Cellectar Biosciences Inc. From 05/24/19

Clinical stage biopharmaceutical company Cellectar Biosciences (NASDAQ: CLRB) has closed a registered direct offering sale of 1,982,000 common shares and concurrent private placement of 2,018,000 common shares with institutional investors. In conjunction with the offerings, the company issued ...

CIRCOR (NYSE: CIR ) +51%  on Crane buyout offer . More news on: CIRCOR International, Inc., JMU Limited, Biocept, Inc., Stocks on the move, Read more ...

FLORHAM PARK, N.J., May 21, 2019 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced that initial results from the th...

FLORHAM PARK, N.J., May 20, 2019 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced that it closed its previously announc...

Gainers:  Eltek (NASDAQ: ELTK ) +70% . Iovance Biotherapeutics (NASDAQ: IOVA ) +33% . Adverum Biotechnologies (NASDAQ: ADVM ) +25% . Charah Solutions (NYSE: CHRA ) +19% . KEMET Corporation (NYSE: KEM ) +17% . Mirati Therapeutics (NASDAQ: MRTX ) +16% . Danaos Corporation (NYSE: D...

Cellectar Biosciences ( CLRB -25.4% ) obliterates yesterday's  24%  spike with its $10M direct stock offering to institutional investors. More news on: Cellectar Biosciences, Inc., Healthcare stocks news, Stocks on the move, Read more ...

Virtusa (NASDAQ: VRTU )  -24%  on Q4 earnings . More news on: Virtusa Corporation, Cellectar Biosciences, Inc., EDAP TMS S.A., Stocks on the move, Read more ...

FLORHAM PARK, N.J., May 16, 2019 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced that it has entered into definitive a...

May 16, 2019 Palm Beach, FL –May 16, 2019 –  The initial diagnosis and the 2 nd opinions all show that the global medical device markets are projected to have a very healthy revenue prognosis through 2014.  In the 2018 edition of the EvaluateMedTech® ...

CLRB stock has been on a tear for the better part of the early hours of trading in Wednesday’s session after Cellectar Biosciences Inc (NASDAQ:CLRB) announced major positive news related to one of its flagship drugs. The drug in question is CLR131 and once the initial results of ...